SIAL Innovation Awards Prize Winners 2024
SIAL Innovation is a global food innovation observatory, run in partnership with ProtéinesXTC, that reviews thousands of applications submitted by the show’s exhibitors every two years.
Through SIAL Innovation, SIAL Paris recognises these innovations through about twenty theme-based awards allocated by category (dairy, seafood, frozen food, etc.), as well as special awards like the Own the Change (CSR) Awards, the Start-up Awards, and the Public’s Choice Awards for which the SIAL Paris ecosystem is invited to vote before and during the show. This 2024 edition features new special prizes such as the Top 3 Countries Awards, for the pick of the nations that have offered the most innovative products, and the Africa Awards. SIAL Paris is a trendsetter and offers visitors a unique insight into the future of global food through a dedicated area at the show featuring products from the SIAL Innovation selection.
INNOVATION BOOSTED IN 2024
Quality and quantity: the SIAL Innovation 2024 Awards showcase the agri-food sector's adaptability and dynamism.
Recent crises like the Covid-19 pandemic, the war in Ukraine, and rising inflation have shifted innovation from focusing on healthy, natural, and ethical topics to addressing a need for comfort.
"Sustainable pleasure" is emerging, combining ecological and wellness goals with a lighter approach. This challenge has been embraced by market players, as shown by over 2,000 new products presented at SIAL Innovation, envisioning a greener and more enjoyable future.
AWARDS CEREMONY SIAL INNOVATION
The highly anticipated SIAL Innovation Gold, Silver and Bronze Awards as well as the Public’s Choice and the Top 3 Countries Awards will be unveiled at the awards ceremony, an unmissable event at the show!
Saturday 19 October 2024 from 4pm to 6pm
SIAL Talks HALL 5A stage.
A TASTE FOR INNOVATION
For the first time, visitors of the show will have the opportunity to taste products from the SIAL Innovation selection in a new area: SIAL Taste. 15-minute tasting sessions for the duration of the show. Open to all, without reservation.
CLICK HERE TO SEE THE AWARDS BY SECTOR
GET YOUR BADGE TO EXPERIENCE
SIAL PARIS’ ANNIVERSARY EDITION
About SIAL Paris
Organised by Comexposium, SIAL Paris is the largest food industry trade fair in the world with more than 7,500 exhibitors and 400,000 exhibited products. The event is part of the SIAL Network, the world’s largest network of food and drink trade fairs. Through eleven regular events, the network brings together 17,000 exhibitors and 700,000 professionals from over 200 countries. The next SIAL Paris will be held from 19 to 23 October 2024 at Paris Nord Villepinte. www.sialparis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241011790020/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom